Compare Merck & Co., Inc. (MRK) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while ABRDN Physical Gold Shares ETF trades at $39.25. The key difference: Merck & Co., Inc. pays a 2.73% dividend while ABRDN Physical Gold Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SGOL | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $51.41 |
52-Week Low | $77.60 | $31.18 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SGOL is trading at $38.16, down 0.16% with bearish technical signals dominating. The stock shows 16 sell signals versus only 1 buy signal across technical indicators, with moving averages indicating strong bearish momentum. Recent gold market volatility and interest rate expectations are creating headwinds for gold-related assets. The stock lacks available fundamental data for traditional valuation metrics.
The outlook remains cautious given the bearish technical setup and gold market uncertainty. Investment opportunities exist for contrarian investors betting on gold's safe-haven appeal amid geopolitical tensions. Key risks include continued interest rate pressure, gold price volatility, and the stock's technical weakness potentially extending further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
